Stratus and Zeto Announce Strategic Distribution Partnership to Expand Access to Point-of-Care EEG in Hospitals Nationwide

Partnership pairs Zeto's rapid, full-montage EEG headsets with Stratus' nationwide network of Registered EEG Technologists, giving hospitals a scalable path to high-quality, continuous EEG data in the ICU and ED.

IRVING, Texas and RALEIGH, N.C., Oct. 15, 2026 /PRNewswire-PRWeb/ -- Stratus, a leading provider of neurodiagnostic solutions in the United States, and Zeto, Inc., a next-generation neurotechnology company, today announced a strategic partnership under which Stratus will become an exclusive channel distributor of Zeto's FDA-cleared point-of-care Zeto ONE™ EEG in hospitals. The collaboration combines Zeto's novel, rapid-application EEG hardware and AI-tools with Stratus' clinical operations and nationwide network of Registered EEG Technologists (R. EEG T.s), giving hospitals a single, turnkey path to reliable, continuous EEG monitoring in the ICU, ED, and beyond.

"EEG remains one of the most under-resourced diagnostic tools in acute care, constrained less by clinical demand than by a chronic, nationwide shortage of qualified EEG Technologists," said Charlie Alvarez, Chief Executive Officer at Stratus. "Hospitals need EEG devices that are fast and intuitive enough for bedside staff to apply at the point of care, without sacrificing the full-montage signal quality and continuous, technologist-verified oversight that neurologists rely on to catch critical neurological events as they happen. The Stratus-Zeto partnership is designed to close that gap."

"Zeto is driven by a simple idea: access to high-quality EEG should not be determined by where a patient happens to be or whether a specialized EEG team is immediately available," said Florian Strelzyk, PhD, Chief Executive Officer at Zeto. "Our technology is designed to expand EEG access across the continuum of care, from routine testing to the emergency department, ICU and other settings where timely brain monitoring can change clinical decision-making. Stratus brings tremendous depth in EEG services and Technologist expertise. By bringing that depth together with the breadth of Zeto's platform, we are building a more complete EEG ecosystem and making high-quality brain monitoring available to far more patients."

The partnership builds on an existing clinical relationship between the two companies. Earlier this year, Zeto and Stratus jointly launched NeuroNotis™, a report that pairs Zeto ONE's AI-enabled seizure burden detection with technical validation from Stratus' Registered EEG Technologists. Zeto brings rapid, guided setup and full-head coverage, including synchronized video and ECG to the bedside, while Stratus' remote R. EEG T.s provide the 24/7, eyes-on monitoring and technical review that helps turn raw data into clinically actionable data. This distribution partnership extends that model across Zeto's hospital product offerings, positioning both companies to scale point-of-care EEG access to health systems nationwide.

Zeto ONE™ is now available in hospitals through Stratus. To learn more about this partnership, watch this video.

About Stratus

Stratus is a leading provider of EEG solutions in the United States and offers global EEG technology via the Stratus EEG software. Stratus offers an array of EEG solutions, from remote ICU and EMU monitoring to world-class EEG review software, ambulatory VEEGs with pruned data, and other custom EEG solutions to fit hospitals' needs. The company also provides EEG solutions for centralized and decentralized clinical trials, biomarker detection, and access to over 2.2 million hours of anonymized EEG data through its R&D division's database. To learn more, visit www.stratusneuro.com.

About Zeto

Zeto, Inc., a trailblazer in next-generation neurotechnology, is striving to include an EEG in every relevant health care decision and make brain health insights as common as other vital signs. Powered by its FDA-cleared EEG platform, Zeto enables scalable, real-time measurement of brain activity and provides actionable data to support clinical decision-making, bringing brain monitoring into everyday care environments. The company plans to leverage its platform technology to improve access and quality of medical EEG testing and to facilitate adjacent biomedical research and clinical trials. Zeto's EEG systems, which received FDA clearances in 2018, 2024, and 2026, are commercially available in the United States. To learn more, visit https://zeto-inc.com/.